Author:
Buzdar Aman U.,Coombes R. Charles,Goss Paul E.,Winer Eric P.
Reference19 articles.
1. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
2. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial
3. ; on Behalf of the ATAC Trialists' Group. A detailed analysis of the benefits of anastrozole over tamoxifen for venous thromboembolic events (VTEs) after 5 years treatment. Presented at the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 14-17, 2006. Abstract 104.
4. Peripheral Bone Status in Rheumatoid Arthritis Evaluated by Digital X-Ray Radiogrammetry and Compared with Multisite Quantitative Ultrasound
5. ; on behalf of the ATAC Trialists' Group. Anastrozole is associated with a lower risk of endometrial abnormalities than tamoxifen: first report of the ATAC trial endometrial subprotocol at 6 years' follow-up [poster 4055]. Presented at the San Antonio Breast Cancer Symposium, San Antonio, Tex, December 14-17, 2006.
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献